Current Hematologic Malignancy Reports

, Volume 12, Issue 3, pp 251–256 | Cite as

The Management of Lymphoma in the Setting of Pregnancy

  • Chelsea C Pinnix
  • Therese Y. Andraos
  • Sarah Milgrom
  • Michelle A. Fanale
B-cell NHL, T-cell NHL, and Hodgkin Lymphoma (D Persky, Section Editor)
Part of the following topical collections:
  1. Topical Collection on B-cell NHL, T-cell NHL, and Hodgkin Lymphoma


The diagnosis of lymphoma in pregnant patients poses a therapeutic challenge necessitating consideration of the developing fetus without compromise of therapy with curative potential for the mother. The decision to initiate therapy during pregnancy is heavily influenced by fetal, maternal, and disease-related factors, of which the most influential are the trimester at diagnosis, the stage, and aggressiveness of the disease and the presence of life-threatening symptoms. Recent data suggest that deferral of therapy until after the first trimester is desirable if it is perceived that postponement of therapy will not compromise maternal outcome. For some patients, delay of therapy to the postpartum period is feasible.


Lymphoma Pregnancy Hodgkin lymphoma Therapy 


Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Pavlidis NA. Coexistence of pregnancy and malignancy. Oncologist. 2002;7:279–87.CrossRefPubMedGoogle Scholar
  2. 2.
    Van Calsteren K, Heyns L, De Smet F, et al. Cancer during pregnancy: an analysis of 215 patients emphasizing the obstetrical and the neonatal outcomes. J Clin Oncol. 2010;28:683–9.CrossRefPubMedGoogle Scholar
  3. 3.
    Amant F, Vandenbroucke T, Verheecke M, et al. Pediatric outcome after maternal cancer diagnosed during pregnancy. N Engl J Med. 2015;373:1824–34.CrossRefPubMedGoogle Scholar
  4. 4.
    Engert A, Plutschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med. 2010;363:640–52.CrossRefPubMedGoogle Scholar
  5. 5.
    Woitek R, Prayer D, Hojreh A, Helbich T. Radiological staging in pregnant patients with cancer. ESMO Open. 2016;1:e000017.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Okuda Y, Sagami F, Tirone P, et al. Reproductive and developmental toxicity study of gadobenate dimeglumine formulation (E7155) (3)--study of embryo-fetal toxicity in rabbits by intravenous administration. J Toxicol Sci. 1999;24(Suppl 1):79–87.CrossRefPubMedGoogle Scholar
  7. 7.
    Kennedy EV, Iball GR, Brettle DS. Investigation into the effects of lead shielding for fetal dose reduction in CT pulmonary angiography. Br J Radiol. 2007;80:631–8.CrossRefPubMedGoogle Scholar
  8. 8.
    • Rimawi BH, Green V, Lindsay M. Fetal implications of diagnostic radiation exposure during pregnancy: evidence-based recommendations. Clin Obstet Gynecol. 2016;59:412–8. Evidence-based recommendations for diagnostic radiographic studies during pregnancy with concise review of radiation doses associated with fetal risk as well as radiation doses from standard radiological studies CrossRefPubMedGoogle Scholar
  9. 9.
    Brent RL. The effect of embryonic and fetal exposure to x-ray, microwaves, and ultrasound: counseling the pregnant and nonpregnant patient about these risks. Semin Oncol. 1989;16:347–68.PubMedGoogle Scholar
  10. 10.
    Martin DD. Review of radiation therapy in the pregnant cancer patient. Clin Obstet Gynecol. 2011;54:591–601.CrossRefPubMedGoogle Scholar
  11. 11.
    Loibl S, Han SN, von Minckwitz G, et al. Treatment of breast cancer during pregnancy: an observational study. Lancet Oncol. 2012;13:887–96.CrossRefPubMedGoogle Scholar
  12. 12.
    Abdel-Hady el S, Hemida RA, Gamal A, et al. Cancer during pregnancy: perinatal outcome after in utero exposure to chemotherapy. Arch Gynecol Obstet. 2012;286:283–6.Google Scholar
  13. 13.
    •• Evens AM, Advani R, Press OW, et al. Lymphoma occurring during pregnancy: antenatal therapy, complications, and maternal survival in a multicenter analysis. J Clin Oncol. 2013;31:4132–9. Largest multi-institutional study of 90 patients with lymphoma diagnosed during pregnancy. There was no significant difference in maternal or fetal complications between the women that received antenatal therapy as compared to those who had treatment deferred to the postpartum period. No patient received treatment during the first trimester of pregnancy CrossRefPubMedGoogle Scholar
  14. 14.
    •• Pinnix CC, Osborne EM, Chihara D, et al. Maternal and fetal outcomes after therapy for Hodgkin or non-Hodgkin lymphoma diagnosed during pregnancy. JAMA Oncol. 2016;2:1065–9. Single institutional study of 39 patients diagnosed with lymphoma while pregnant at MDACC. There was no statistically significant difference in maternal outcome according to receipt of antenatal therapy. Four miscarriages occurred, all among patients treated during pregnancy, with 2 of the 4 occurring in patients that receive first trimester therapy CrossRefPubMedGoogle Scholar
  15. 15.
    • Avivi I, Farbstein D, Brenner B, Horowitz NA. Non-Hodgkin lymphomas in pregnancy: tackling therapeutic quandaries. Blood Rev. 2014;28:213–20. Case-based review of the diagnostic and therapeutic challenges of NHL diagnosed during pregnancy CrossRefPubMedGoogle Scholar
  16. 16.
    Bachanova V, Connors JM. Hodgkin lymphoma in pregnancy. Curr Hematol Malig Rep. 2013;8:211–7.CrossRefPubMedGoogle Scholar
  17. 17.
    Hodgson DC, Mikhaeel NG. Consolidative radiation in DLBCL: Evidence-based recommendations. Curr Oncol Rep. 2015;17:49.CrossRefPubMedGoogle Scholar
  18. 18.
    Ng AK, Dabaja BS, Hoppe RT, et al. Re-examining the role of radiation therapy for diffuse large B-cell lymphoma in the modern era. J Clin Oncol. 2016;34:1443–7.CrossRefPubMedGoogle Scholar
  19. 19.
    Cygler J, Ding GX, Kendal W, Cross P. Fetal dose for a patient undergoing mantle field irradiation for Hodgkin’s disease. Med Dosim. 1997;22:135–7.CrossRefPubMedGoogle Scholar
  20. 20.
    Mazonakis M, Varveris H, Fasoulaki M, Damilakis J. Radiotherapy of Hodgkin’s disease in early pregnancy: embryo dose measurements. Radiother Oncol. 2003;66:333–9.CrossRefPubMedGoogle Scholar
  21. 21.
    Woo SY, Fuller LM, Cundiff JH, et al. Radiotherapy during pregnancy for clinical stages IA-IIA Hodgkin’s disease. Int J Radiat Oncol Biol Phys. 1992;23:407–12.CrossRefPubMedGoogle Scholar
  22. 22.
    Chakravarty EF, Murray ER, Kelman A, Farmer P. Pregnancy outcomes after maternal exposure to rituximab. Blood. 2011;117:1499–506.CrossRefPubMedGoogle Scholar
  23. 23.
    Mandal PK, Dolai TK, Bagchi B, et al. B cell suppression in newborn following treatment of pregnant diffuse large B-cell lymphoma patient with rituximab containing regimen. Indian J Pediatr. 2014;81:1092–4.CrossRefPubMedGoogle Scholar
  24. 24.
    Burnette BL, Jentoft MA, Porrata LF, et al. Single-agent rituximab for primary CNS lymphoma during pregnancy as a bridge to definitive management. J Clin Oncol. 2014;32:e14–7.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    •• Amant F, Van Calsteren K, Halaska MJ, et al. Long-term cognitive and cardiac outcomes after prenatal exposure to chemotherapy in children aged 18 months or older: an observational study. Lancet Oncol. 2012;13:256–64. Multicenter case-control study of 129 children born to mothers diagnosed with cancer during pregnancy matched to children of mothers without cancer. Gestational age at the time of delivery (i.e., prematurity) was associated with inferior cognitive outcome in both groups. There was no adverse effect of antenatal therapy detected in this study CrossRefPubMedGoogle Scholar
  26. 26.
    Maternal Cancer During Pregnancy and Risks of Stillbirth and Infant Mortality. Lu D, Ludvigsson JF, Smedby KE, Fall K, Valdimarsdóttir U, Cnattingius S, Fang F. J Clin Oncol. 2017 Mar 6:JCO2016699439. doi: 10.1200/JCO.2016.69.9439. [Epub ahead of print] PMID: 28384079
  27. 27.
    Weibull CE, Eloranta S, Smedby KE, et al. Pregnancy and the risk of relapse in patients diagnosed with Hodgkin lymphoma. J Clin Oncol. 2016;34:337–44.CrossRefPubMedGoogle Scholar
  28. 28.
    Amant F, Verheecke M, Wlodarska I, et al. Presymptomatic identification of cancers in pregnant women during noninvasive prenatal testing. JAMA Oncol. 2015;1:814–9.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  • Chelsea C Pinnix
    • 1
  • Therese Y. Andraos
    • 1
  • Sarah Milgrom
    • 1
  • Michelle A. Fanale
    • 2
  1. 1.Department of Radiation OncologyUniversity of Texas MD Anderson Cancer CenterHoustonUSA
  2. 2.Lymphoma/MyelomaUniversity of Texas MD Anderson Cancer CenterHoustonUSA

Personalised recommendations